Clywedog Therapeutics Launches Phase 1b Study for Balomenib in Type 2 Diabetes Clywedog Therapeutics has announced the activation of all clinical centers and patient dosing in a Phase 1b study evaluating Balomenib for Type 2 Diabetes. This marks a key milestone for the company's innovative treatment approach.

Clywedog Therapeutics Launches Phase 1b Study for Balomenib in Type 2 Diabetes #USA #Dover #Type_2_Diabetes #Clywedog #Balomenib